Loading...
Loading...
NOVARTIS AG
NOVARTIS AG. Spoken Alpha tracks NVSEF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks NVSEF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NVSEF.
curl https://api.spokenalpha.com/v1/companies/NVSEF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.73 | $4.15 | +38.1% | +0.7% | +3.1% |
| Q4 FY2026 | $5.53 | $4.13 | +33.9% | +0.9% | +0.5% |
| Q3 FY2026 | $5.83 | $3.97 | +46.9% | -3.0% | -5.6% |
| Q2 FY2026 | $5.66 | $3.98 | +42.2% | +2.2% | +3.5% |
| Q1 FY2025 | $5.49 | $4.03 | +36.2% | +0.2% | -2.3% |
| Q4 FY2025 | $5.68 | $4.10 | +38.5% | -3.0% | -0.9% |
| Q3 FY2025 | $5.99 | $4.29 | +39.6% | -6.1% | -6.8% |
| Q2 FY2025 | $6.14 | $4.28 | +43.4% | -3.7% | -6.0% |
| Q1 FY2024 | $5.61 | $4.11 | +36.4% | +3.3% | +4.9% |
| Q4 FY2024 | $5.78 | $4.26 | +35.7% | -8.2% | -5.5% |